{"allTrials": {"@totalCount": "11", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "16", "isrctn": {"@dateAssigned": "2008-02-14T00:00:00.000Z", "#text": "86666250"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Efficacy and tolerance of tazarotene cream in lamellar ichthyosis (LI): a dose-finding study", "scientificTitle": null, "acronym": null, "studyHypothesis": "The short term efficacy and safety of the tazarotene cream at two different dosages need to be assessed and compared in (lamellar ichthyosis) LI patients, using an intra-individual design (left/right comparison of tazarotene 0.1% versus tazarotene 0.05% versus vehicle), as a pre-requisite of the phase III pivotal study. \n\nAs of 14/08/2009, this record has been updated to include an extended anticipated end date; the initial anticipated end date was 31/12/2008.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Assessment of scaling and roughness by the investigator at each of the 10 visits (at screening, baseline, then on days 7, 14, 21, 28 [end of treatment, Period I], 42, 56, 70 and 84 [end of treatment-free follow-up, Period II]).", "secondaryOutcome": "1. Assessment of the relapse/rebound by the investigator during Period II\n2. Time-course severity of each sign (scaling and roughness) during Periods I and II\n3. Separate assessment of the overall clinical severity of the lesions on palms and soles for each test side of the body at baseline and end of Period I\n4. Assessment of the severity of scaling at baseline and end of Period I\n5. Instrumental assessment of scaling on the two forearms using the D-squame technique, at baseline and end of Period I\n6. Global local tolerance at end of Period I\n7. Overall acceptability by the patients at end of Period I\n8. Routine blood laboratory tests (hematology, chemistry) at baseline and at end of Period I\n9. Plasma monitoring of tazarotenic acid at baseline and at end of Period I\n10. Compliance\n11. Physical examination\n12. Adverse events", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "France:\n1. Ethics committee for protection of biomedical research subjects (Comite de Protection des Personnes), Ile de France II (for all four centres), approved on 11 December 2007\n\nGermany:\nApproval obtained from the following ethics committees on 22 November 2007:\n1. Ethics committee of the Ludwig-Maximilians University (LMU) Munich, Faculty of Medicine\n2. Ethics committee of the Hamburg Clinic\n3. Ethics committee of the Westfalen-Lippe Clinic and the Faculty of Medicine, University of M\u00fcnster (WWU M\u00fcnster)\n4. Ethics Committee of the Georg-August University Goettingen, Faculty of Medicine\n5. Berlin State Health and Social Ethics Committee (Landesamt F\u00fcr Gesundheit Und Soziales, Gesch\u00e4ftsstelle Der Ethik-Kommission Des Landes Berlin)\n6. Ethics Committee of the Heinreich-Heine University D\u00fcsseldorf, Faculty of Medicine"}, "externalRefs": {"doi": "10.1186/ISRCTN86666250", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "R00002 CR 2 01 (ORF)"}, "trialDesign": {"studyDesign": "Period I (4 weeks): Randomised double-blind vehicle-controlled right/left comparison\nPeriod II (8 weeks): Double-blind comparative treatment-free follow-up", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Screening"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-09-01T00:00:00.000Z", "overallEndDate": "2009-04-20T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["France", "Germany"]}, "trialCentres": {"trialCentre": {"@id": "08ce1733-5e0f-4046-bf30-93a0773f597d", "name": "4 Rue Marie Curie", "address": null, "city": "Ramonville St Agne", "state": null, "country": "France", "zip": "31521"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Patients of both sexes of at least 8 years of age\n2. Patients with a documented diagnosis of LI based on clinical signs and, if possible, pedigree analysis\n3. Patients with both scaling and roughness of moderate to severe intensity on each side of the body\n4. Patients or patient's parents/guardians able to understand and follow the study procedures\n5. Written informed consent from the patients or parents/guardians\n6. Patients or patients' parents/guardians affiliated to a healthcare security system", "ageRange": "Other", "gender": "Both", "targetEnrolment": "30", "totalFinalEnrolment": null, "totalTarget": "Added 14/08/2009: 30 participants (initial target: 32)", "exclusion": "1. Patients under 8 years of age \n2. Pregnant women, lactating mothers or women of childbearing potential with no reliable medical contraception (combined oral contraceptive, intra-uterine contraceptive device) and unwilling to use condoms, up to 8 weeks after the last test product application\n3. Women of childbearing potential with a positive systemic pregnancy test at baseline\n4. Patients with congenital ichthyoses other than LI\n5. Patients with an erythrodermic component of LI (EARLI)\n6. Patients with LI of mild severity on at least one side of the body\n7. Patients with lesional superinfection\n8. Patients with skin or systemic disease likely to interfere with the study or the evaluation parameters\n9. Patients with a known contact allergy to one of the ingredients contained in the test products\n10. Patients with sunburn, or excessive pruritus, burning, skin redness or peeling, not fully recovered\n11. Patients treated with topicals (e.g., vitamin A analogues, vitamin D analogues) within 14 days prior to baseline\n12. Patients treated with keratolytics (e.g., urea, hydroxy-acids) or moisturizers other than the standard moisturizer within 7 days prior to baseline\n13. Patients treated with concomitant dermatological medications and cosmetics that have a strong drying effect within 7 days prior to baseline\n14. Patients treated with oral retinoids during the preceding 28 days, or with oral vitamin A supplementation (more than 3000 IU per day) during the preceding 7 days of baseline\n15. Patients treated with drugs known to be photosensitizers (e.g., thiazides, tetracyclines, quinolones, phenothiazines, sulfonamides, hydrochlorates, chlorpromazine, psoralen, amiodarone, tar) within 2 weeks prior to baseline\n16. Patients treated with UV therapy or patients medically exposed to UV within 4 weeks prior to baseline\n17. Patients having significant sun exposure due to their occupation\n18. Patients with inherent sensitivity to sunlight\n19. Patients who participated in a study within the 3 months prior to study entry\n20. Patients living with a family member who is currently under test treatment, i.e. Period I of the study (from baseline to day 28)\n21. Patients or patients' parents/guardians who are unable to understand and/or to follow the study procedures and patient instructions\n22. Patients or patients' parents/guardians who are unwilling to give written informed consent", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2007-09-01T00:00:00.000Z", "recruitmentEnd": "2009-04-20T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Non Erythrodermic Autosomic Recessive Lamellar Ichthyosis (NEARLI)", "diseaseClass1": "Other", "diseaseClass2": "Congenital ichthyosis"}}, "interventions": {"intervention": {"description": "Study treatments: \nTazarotene cream 0.1% or 0.05% and vehicle. \n\nDose: \nPeriod I (4 weeks): Patients will apply one of the two active test products and the vehicle on the lesions (except on face, scalp, neck and genital areas), on two randomly allocated sides (left side and right side of the body) once daily for 4 weeks (e.g., every evening). This will be associated with the daily application of a standard moisturiser (e.g., in the morning; including face and neck). An adjusted dosage to local tolerance of test products will be performed (no test product application on irritated areas on days when they are observed). \n\nPeriod II (8 weeks): No application of the test products for 8 weeks; application of the standard moisturiser only. \n\nMode of administration: \nTopical", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Tazarotene"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17461-0", "contactId": "Contact55423_17461", "sponsorId": "Sponsor54003"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55423_17461", "title": "Miss", "forename": "Caroline", "surname": "Miklaszewski", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "4 Rue Marie Curie \nBP22132", "city": "Ramonville St Agne", "country": "France", "zip": "31521", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54003", "organisation": "Orfagen (France)", "website": "http://www.orfagen.com", "sponsorType": "Industry", "contactDetails": {"address": "4 Rue Marie Curie BP22132", "city": "Ramonville St Agne", "country": "France", "zip": "31521", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder17461-0", "name": "Orfagen (France)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-02-14T00:00:00.000Z", "#text": "87577685"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "FES: FESS Effectiveness Study: a multi-centre randomised controlled trial studying the effectiveness of functional endoscopic sinus surgery (FESS) in adult patients with chronic rhinosinusitis/nasal polyps unresponsive to medical therapy", "scientificTitle": null, "acronym": "FES", "studyHypothesis": "FESS is effective: giving significant reduction of symptoms. \nThe indication for FESS must be based on the symptoms of the patient and its duration, computed tomography (CT) scan abnormalities and/or nasal endoscopic abnormalities, and a history of adequate conservative treatment.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The primary outcome measure is a validated disease-specific quality of life questionnaire: SNOT-20.", "secondaryOutcome": "The secondary endpoint is re-evaluation of the indication for FESS. Another secondary endpoint will be the standardised evaluation of the nasendoscopy and the CT-scan. For the efficiency assessment 2 secondary endpoints will be evaluated: days of sick-leave and a work-productivity questionnaire.", "trialWebsite": "http://www.fess.nl", "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN87577685", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR558"}, "trialDesign": {"studyDesign": "Multicentre randomised open label active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-01-01T00:00:00.000Z", "overallEndDate": "2008-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "afe3c979-8ad7-4042-ab07-62478dfc6ad5", "name": "Academic Medical Center, Amsterdam", "address": null, "city": "Almere", "state": null, "country": "Netherlands", "zip": "1100 DD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Males or females aged 18 years old can participate\n2. Diagnosis CRS with/without NP (definition according to the European Position Paper on Rhinosinusitis and Nasal Polyposis [EPOS])\n3. Prior treatment as defined in the treatment scheme of the protocol for at least 12 weeks\n4. No prior sinus surgery\n5. Indication for FESS, both criteria must be met: \n5.1. RSOM-31 (add score of magnitude of questions 1, 2, 4, 22 result >9)                    \n5.2. CT score >3 on 1 side at least, judged on a CT-scan made prior to visit 1 and made less than 4 months ago; Lund/Mackay scoring\n6. Written informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "160", "totalFinalEnrolment": null, "totalTarget": "160", "exclusion": "1. Cystic fibrosis \n2. Gross immunodeficiency (congenital or acquired)\n3. Congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)\n4. Non-invasive fungal balls and invasive fungal disease\n5. Systemic vasculitis and granulomatous diseases\n6. Patients who have any serious or unstable concurrent disease\n7. Any structural nasal abnormalities (other than polyps or chronic sinusitis) e.g. severe nasal septum deviation\n8. Rhinosurgery during the past 6 weeks\n9. Systemic steroids 4 weeks before the study\n10. Medication affecting nasal mucosa (cyclosporin, \u00df-blocker, ACE inhibitors, non-steroidal anti-inflammatory drugs [NSAIDs], reserpine, guanethidinge, phenolomine, methyldopa, alfa-adrenoceptor antagonist and chlorpromazine)\n11. Medication other than trial medication\n12. Females who are pregnant or lactating\n13. Inability to follow the instructions within this protocol or known inability to attend ALL clinical visits within the intervals stated", "patientInfoSheet": null, "recruitmentStart": "2006-01-01T00:00:00.000Z", "recruitmentEnd": "2008-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Chronic rhinosinusitis (CRS), nasal polyps (NP)", "diseaseClass1": "Ear, Nose and Throat", "diseaseClass2": "1. Chronic sinusitis \n2. Nasal polyp"}}, "interventions": {"intervention": {"description": "The intervention to be investigated is Functional Endoscopic Sinus Surgery (FESS). One treatment arm will receive FESS plus a standardised form of medical treatment. The control group will receive standardised medical treatment. The standardised medical treatment is topical steroids for mild CRS (without NP). In moderate/severe disease a long-term antibiotic is added. The therapy for NP will be corticosteroids. For mild NP therapy is a spray, for moderate disease therapy is a spray and drops, and for severe disease therapy is oral steroids with drops. Specific details are in the protocol.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14794-0", "contactId": "Contact52564_14794", "sponsorId": "Sponsor51088"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52564_14794", "title": "Prof", "forename": "W.J.", "surname": "Fokkens", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Academic Medical Center, Amsterdam\nDepartment of Otorhinolaryngology\nRoom A2-234\nP.O. Box 22660", "city": "Almere", "country": "Netherlands", "zip": "1100 DD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 5663789"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "W.J.Fokkens@amc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51088", "organisation": "Academic Medical Centre (AMC) (Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "ENT Department\nP.O. Box 22660", "city": "Amsterdam", "country": "Netherlands", "zip": "1100 DD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5650.6", "rorId": "https://ror.org/03t4gr691"}, "funder": {"@id": "Funder14794-0", "name": "Academic Medical Centre (AMC) (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "23173889"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Molecular determinants of bone mineral density (BMD) in children with acute lymphoblastic leukemia (ALL) and the role of intervention by physical activities and calcium and vitamin D supplements as a preventive strategy", "scientificTitle": null, "acronym": null, "studyHypothesis": "Intervention with adequate calcium and vitamin D and physical activities will influence BMD and fracture rate in a positive way during and after treatment for childhood ALL.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Increase of BMD", "secondaryOutcome": "Decrease of fracture rate", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN23173889", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR477; MEC number 193.291/2000/144 and 114.720/1991/62"}, "trialDesign": {"studyDesign": "Randomised single blind placebo controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2001-09-01T00:00:00.000Z", "overallEndDate": "2004-10-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "e82acc2e-5f07-4e53-8083-5e42deae81c4", "name": "Erasmus Medical Center", "address": null, "city": "Rotterdam", "state": null, "country": "Netherlands", "zip": "3000 CB"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Patients aged 4-18 with ALL", "ageRange": "Child", "lowerAgeLimit": {"@unit": "Years", "@value": "4.0"}, "upperAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "80", "totalFinalEnrolment": null, "totalTarget": "80", "exclusion": "1. Physical handicap\n2. Age <3 years", "patientInfoSheet": null, "recruitmentStart": "2001-09-01T00:00:00.000Z", "recruitmentEnd": "2004-10-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Acute Lymphoblastic Leukemia (ALL)", "diseaseClass1": "Cancer", "diseaseClass2": "Lymphoid leukaemia"}}, "interventions": {"intervention": {"description": "Controlled physical activities", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14708-0", "contactId": "Contact52467_14708", "sponsorId": "Sponsor50982"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52467_14708", "title": "Dr", "forename": "R.D.", "surname": "Beek, van", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Erasmus Medical Center\nSophia Children\u0092s Hospital\nDepartment of Pediatrics\nP.O. Box 2060", "city": "Rotterdam", "country": "Netherlands", "zip": "3000 CB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "r.d.vanbeek@erasmusmc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50982", "organisation": "Erasmus Medical Center, Sophia Children's Oncology Center Rotterdam (KOCR) (Netherlands)", "website": null, "sponsorType": "Not defined", "contactDetails": {"address": "P.O. Box 2060", "city": "Rotterdam", "country": "Netherlands", "zip": "3000 CB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)10 4636691"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "j.dito@erasmusmc.nl"}}, "privacy": "Public", "gridId": "grid.5645.2", "rorId": "https://ror.org/018906e22"}, "funder": {"@id": "Funder14708-0", "name": "Erasmus Medical Centre, Sophia Children's Oncology Centre, Rotterdam (KOCR)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "85367943"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Patient satisfaction in the treatment of anal fissure", "scientificTitle": null, "acronym": null, "studyHypothesis": "Treatment of anal fissure with isosorbide dinitrate (ISDN) or Botulinum toxin A gives approximately comparative outcomes. Because of intensive treatment with isosorbide dinitrate cream, patients treated with Botulinum toxin A will be more satisfied. After six weeks treatment with Botulinum toxin A, the patient satisfaction will be significant more than patients treated with isosorbide dinitrate.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Patient satisfaction after 6 weeks\n2. Visual Analogue Score on weeks 0, 6 and 12", "secondaryOutcome": "1. Patient satisfaction after 12 weeks\n2. Pain after defecation at night\n3. Incontinence after 6 and 12 weeks\n4. Healing of fissure after 6 and 12 weeks", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN85367943", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR441; 2004/149"}, "trialDesign": {"studyDesign": "Multicentre randomised single blind active controlled parallel trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-11-08T00:00:00.000Z", "overallEndDate": "2007-07-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "57bcf544-abe7-4cb1-85e9-050f4a38f654", "name": "Sint Lucas Andreas Ziekenhuis", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1006 AE"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Diagnosed anal fissure with complaints\n2. Complaints longer than 2 months\n3. Age 21-60 years\n4. Dutch speaking\n5. Will-competent\n6. Informed consent", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "50", "totalFinalEnrolment": null, "totalTarget": "50", "exclusion": "1. Pregnancy, lactation\n2. Muscle-sicknesses such as myasthenia gravis\n3. Simultaneous use of medication interacting with neuromuscular transmission\n4. Fistulas\n5. Coagulation disorders or the use of anticoagulants\n6. Anal surgery in the past\n7. Haemorrhoids or inflammatory bowel sicknesses as a cause of anal fissure\n8. Major secondary changes because of the anal fissure", "patientInfoSheet": null, "recruitmentStart": "2004-11-08T00:00:00.000Z", "recruitmentEnd": "2007-07-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Anal fissure", "diseaseClass1": "Digestive System", "diseaseClass2": "Fissure and fistula of anal and rectal region"}}, "interventions": {"intervention": {"description": "ISDN 1% cream versus Botuline Toxine A for a duration of 12 weeks.\nISDN cream application every 4 hours for 12 weeks.\nBotulinum Toxin A injection at week 0 and if necessary again at week 6.\nBotulinum Toxin A Dysport\u00ae is made by Ipsen.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Botulinum toxin A (Dysport\u00ae), isosorbide dinitrate"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14693-0", "contactId": "Contact52452_14693", "sponsorId": "Sponsor50967"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52452_14693", "title": "Dr", "forename": "W.F.", "surname": "Tets", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Sint Lucas Andreas Ziekenhuis\nDepartment Surgery\nP.O. Box 9243", "city": "Amsterdam", "country": "Netherlands", "zip": "1006 AE", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "w.vantets@slaz.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50967", "organisation": "Ipsen Farmaceutica B.V. (Netherlands)", "website": "http://www.ipsen.com", "sponsorType": "Not defined", "contactDetails": {"address": "Hoofdweg Oostzijde 620", "city": "Hoofddorp", "country": "Netherlands", "zip": "2132 MJ", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.476475.3", "rorId": "https://ror.org/026jmga48"}, "funder": {"@id": "Funder14693-0", "name": "Ipsen Farmaceutica B.V. (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "36786212"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Intraventricular infusion of rt-PA in severe intraventricular haemorrhage after aneurysmal subarachnoid haemorrhage. A randomised clinical trial.", "scientificTitle": "(Added 14/08/09) Recombinant tissue plasminogen activator (rt-PA) and external ventricular drain (EVD) in subarachnoid haemorrhage (SAH) with obstructive hydrocephalus for lysis of ventricular blood. A randomised clinical trial.", "acronym": "RESOLVE", "studyHypothesis": "Intraventricular infusion of rt-PA reduces the frequency of poor outcome (death or dependency) in patients with a severe intraventricular haemorrhage after aneurysmal subarachnoid hemorrhage.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Death or dependency 6 months after subarachnoid haemorrhage", "secondaryOutcome": "1. Recurrent haemorrhage\n2. Secondary ischaemia\n3. Hydrocephalus\n4. Bleeding complications from fibrinolysis\n5. Death within 6 months\n6. Rankin 0 versus Rankin 1-5 and death", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN36786212", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR455"}, "trialDesign": {"studyDesign": "Single centre prospective randomised double blind placebo controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-09-01T00:00:00.000Z", "overallEndDate": "2009-09-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "1032f4ca-a72d-40c0-9dc4-aaa32066ee89", "name": "University Medical Center Utrecht", "address": null, "city": "Utrecht", "state": null, "country": "Netherlands", "zip": "3584 CX"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. First or recurrent aneurysmal subarachnoid haemorrhage with intraventricular extension of the haemorrhage\n2. The ventricles must be enlarged and the intraventricular haemorrhage must be severe (Graeb-score more than 6)\n3. Patients must be in a poor neurological condition, WFNS <7 or WFNS <6 in intubated patients", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "16", "totalFinalEnrolment": null, "totalTarget": "16", "exclusion": "1. Other cause for intraventricular haemorrhage than a subarachnoid haemorrhage from a ruptured intracranial aneurysm\n2. Absence of both pupillary light reflexes\n3. Use of oral anticoagulants\n4. Treating physicians propose a palliative instead of curative treatment strategy\n5. Absence of informed consent", "patientInfoSheet": null, "recruitmentStart": "2005-09-01T00:00:00.000Z", "recruitmentEnd": "2009-09-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Aneurysmal subarachnoid haemorrhage, Hydrocephalus, Intraventricular haemorrhage", "diseaseClass1": "Circulatory System", "diseaseClass2": "Other cerebrovascular diseases"}}, "interventions": {"intervention": {"description": "1. Placement of external ventricular drain (standard procedure)\n2. Clipping/Coiling of ruptured aneurysm (standard procedure)\n3. Infusion of rt-PA or placebo through external ventricular drain", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14698-0", "contactId": "Contact52457_14698", "sponsorId": "Sponsor50972"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52457_14698", "title": "Dr", "forename": "D.", "surname": "Nieuwkamp", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Medical Center Utrecht\nDepartment of Neurology\nHeidelberglaan 100", "city": "Utrecht", "country": "Netherlands", "zip": "3584 CX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "d.nieuwkamp@neuro.azu.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50972", "organisation": "University Medical Center Utrecht, Department of Neurology (The Netherlands)", "website": null, "sponsorType": "Not defined", "contactDetails": {"address": "Heidelberglaan 100", "city": "Utrecht", "country": "Netherlands", "zip": "3584 CX", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.7692.a", "rorId": "https://ror.org/0575yy874"}, "funder": {"@id": "Funder14698-0", "name": "University Medical Centre Utrecht (UMCU) (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "22844568"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Randomized phase II/III study of Risedronate in combination with Docetaxel versus Docetaxel alone in patients with hormone refractory prostate cancer", "scientificTitle": null, "acronym": "NePro", "studyHypothesis": "Clinical studies with mitoxantrone and clodronate showed a better pain reduction in patients with prostate cancer. Both in vitro and animal studies have shown that paclitaxel and biphosphonates act synergistically and prevent formation and progression of bone metastasis (breast cancer). This clinical trial studies the effect of risedronate and docetaxel in the treatment of hormone refractory prostate cancer.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Assess the objective PSA response to treatment by serial measurements of serum PSA as defined by the 'Bubley'.\n2. Compare time to progression between concomitant and sequential use of docetaxel and risedronate, in combination with prednisone.", "secondaryOutcome": "Compare the following parameters: \n1. PSA response (Nubley rate)\n2. PPI according to McGIll-Melzack toxicity profile\n3. Objective response (RECIST)\n4. Duration of PSA response\n5. Survival", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical eithics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN22844568", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR469; EMC 03-146"}, "trialDesign": {"studyDesign": "Multicentre randomised open label active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2003-12-15T00:00:00.000Z", "overallEndDate": "2007-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "9ae2b53e-b149-4613-a745-c5ccef541180", "name": "Erasmus Medical Center Rotterdam", "address": null, "city": "Rotterdam", "state": null, "country": "Netherlands", "zip": "3008 AE"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Histologically proven prostate adenocarcinoma\n2. Hormone refractory\n3. Continued elevated PSA for at least 6 weeks after discontinuation of anti-androgens prior to registration; last PSA level >5 ng/ml\n4. Stable analgesic regimen for at least one week prior to registration\n5. Patients without surgical castration must continue on LHRH antagonists\n6. Adequate bone marrow, liver, renal function\n7. WHO 0-2", "ageRange": "Adult", "gender": "Male", "targetEnrolment": "480", "totalFinalEnrolment": null, "totalTarget": "480", "exclusion": "1. Previous or concomitant use of biphosphonates\n2. Prior chemotherapy or radiotherapy within 4 weeks prior to treatment start\n3. Uncontrolled hypercalcemia\n4. Brain metastases\n5. Previous or concomitant malignancies\n6. Uncontrolled systemic disease of infection", "patientInfoSheet": null, "recruitmentStart": "2003-12-15T00:00:00.000Z", "recruitmentEnd": "2007-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Prostate Cancer", "diseaseClass1": "Cancer", "diseaseClass2": "Malignant neoplasm of prostate"}}, "interventions": {"intervention": {"description": "Arm A: Docetaxel 75 mg/m2 every 3 weeks. Every patient will receive prednisone 5 mg bid.\nArm B: Docetaxel 75 mg/m2 every 3 weeks plus 30 mg Risedronate once daily. Every patient will receive prednisone 5 mg bid.\nTreatment will be given until progression, or 10 courses. After progression Risedronate 30 mg od + prednisone 5 mg will be continued.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": ["Funder14706-0", "Funder14706-1"], "contactId": "Contact52465_14706", "sponsorId": "Sponsor50980"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52465_14706", "title": "Dr", "forename": "R", "surname": "de Wit", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Erasmus Medical Center Rotterdam\nDepartment of Medical Oncology\nP.O. Box 5201", "city": "Rotterdam", "country": "Netherlands", "zip": "3008 AE", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor50980", "organisation": "Erasmus Medical Centre (Netherlands)", "website": "http://www.erasmusmc.nl", "sponsorType": "University/education", "contactDetails": {"address": "Postbus 2040", "city": "Rotterdam", "country": "Netherlands", "zip": "3000 CA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5645.2", "rorId": "https://ror.org/018906e22"}, "funder": [{"@id": "Funder14706-0", "name": "Sanofi-Aventis B.V. (Netherlands)", "fundRef": null}, {"@id": "Funder14706-1", "name": "Erasmus Medical Centre (Netherlands) (added 10/08/09)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "19", "isrctn": {"@dateAssigned": "2006-01-27T00:00:00.000Z", "#text": "86386707"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "An open, randomized, (out-patient) clinical study into the effectiveness, durability and cost efficiency of Tiscover\u00ae (cultured, autologous skin) for chronic leg wounds (ulcera cruris)", "scientificTitle": null, "acronym": "TISCOVER", "studyHypothesis": "We hypothesize that ulcers treated with Tiscover\u00ae will significantly decrease in size resulting in most cases in full healing, compared to the control group which is not treated with Tiscover\u00ae.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Effectiveness of treatment of therapy resistant, chronic ulcera cruris (>5 months open; >2 months with no sign of healing), with Tiscover\u00ae.", "secondaryOutcome": "1. Determine whether hospitalization and wound bed preparation have a beneficial effect\n2. Evaluate unforeseen toxicity due to Tiscover\u00ae treatment\n3. Evaluate the durability of treatment with Tiscover\u00ae\n4. Determine whether out-patient treatment with Tiscover\u00ae is possible\n5. Compare the costs of Tiscover\u00ae treatment with present costs for caring/treatment of inert ulcera cruris without Tiscover\u00ae", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN86386707", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR439"}, "trialDesign": {"studyDesign": "Multicentre randomised open label active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-10-15T00:00:00.000Z", "overallEndDate": "2007-10-15T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "2e9701d8-25b6-4739-85dc-28d4fa836e18", "name": "VU University Medical Center", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1081 HV"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Ulcus cruris venosum, ulcus cruris arterio(lo)scleroticum and ulcers of mixed origin\n2. Non-vital ulcers which exist for at least 5 months and which do not respond to adequate compression therapy and local wound treatment\n3. Ulcers between 5 and 100 square cm\n4. Signed informed consent\n5. Ankle/arm index >0.7", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "100", "totalFinalEnrolment": null, "totalTarget": "100", "exclusion": "1. Diabetic foot ulcers\n2. Serious co-morbidity which decreases the life expectancy to less than 2 years\n3. Use of high doses of corticosteroids and/or cytostatic drugs (>20 mg/day)\n4. Diagnosed Penicillin allergy\n5. Serious infection of the ulcer bed at time t = 0\n6. Disturbances of psychiatric nature where the following of medical advice becomes a problem\n7. Declining clinical treatment and/or follow up visits", "patientInfoSheet": null, "recruitmentStart": "2005-10-15T00:00:00.000Z", "recruitmentEnd": "2007-10-15T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Ulcera cruris venosa, ulcera cruris arterio(lo)scleroticum, ulcers of mixed origin", "diseaseClass1": "Circulatory System", "diseaseClass2": "Varicose veins of lower extremities"}}, "interventions": {"intervention": {"description": "Two out-patient groups:\nControl group (n = 30): 1 week prior wound bed preparation with acellular allodermis\nTest group (n = 30): 1 week prior wound bed preparation with acellular allodermis followed by removal of allodermis and application of Tiscover\u00ae\n\nTwo in-patient groups:\nControl group (n = 20): 5 day prior wound bed preparation with Vacuum Assisted Closure therapy (VAC)\nTest group (n = 20): 5 day prior wound bed preparation with VAC followed by application of Tiscover\u00ae\n\nAll patients receive compression therapy.\nAll patients have a weekly follow-up for the duration of 24 weeks.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14669-0", "contactId": "Contact52428_14669", "sponsorId": "Sponsor50943"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52428_14669", "title": "Dr", "forename": "E.M.", "surname": "Boer, de", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "VU University Medical Center\nDepartment of Dermatology\nDe Boelelaan 1117", "city": "Amsterdam", "country": "Netherlands", "zip": "1081 HV", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 4444444"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "em.dboer@vumc.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50943", "organisation": "VU University Medical Centre (VUMC) (Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Department of Dermatology \nDe Boelelaan 1117", "city": "Amsterdam", "country": "Netherlands", "zip": "1081 HV", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.16872.3a", "rorId": "https://ror.org/00q6h8f30"}, "funder": {"@id": "Funder14669-0", "name": "The Netherlands Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek [NWO]) (Netherlands) Biopartner First Stage Grant", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2006-01-25T00:00:00.000Z", "#text": "02471586"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Survey of Canadian Family Physicians Attitudes Towards Residency Research Education", "scientificTitle": null, "acronym": null, "studyHypothesis": "Primary goal: to investigate the attitudes of practicing family physicians toward residency research education\nSecondary goal: to assess the effect of survey paper colour on overall response rate", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Attitudes of practicing family physicians toward research education during family medicine residency", "secondaryOutcome": "Survey response rate", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Approved by Research Ethics Board at Sunnybrook (Canada) and by Women's College Health Sciences Centre (Canada) on November 7, 2005 (Protocol #447-2005)"}, "externalRefs": {"doi": "10.1186/ISRCTN02471586", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Postal survey", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Cross-section survey", "trialSettings": {"trialSetting": "GP practice"}, "trialTypes": {"trialType": "Other"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-01-01T00:00:00.000Z", "overallEndDate": "2006-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Canada"}, "trialCentres": {"trialCentre": {"@id": "e1a5f55c-4127-4dd9-acab-924e2453e6a1", "name": "2075 Bayview Avenue", "address": null, "city": "Toronto, ON", "state": null, "country": "Canada", "zip": "M4N 3M5"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Practicing Canadian family physician\n2. Certified by College of Family Physicians of Canada\n3. English as first language", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "500", "totalFinalEnrolment": null, "totalTarget": "500", "exclusion": "1. Registered as emergency room physician\n2. French as first language", "patientInfoSheet": null, "recruitmentStart": "2006-01-01T00:00:00.000Z", "recruitmentEnd": "2006-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Research education during family medicine residency", "diseaseClass1": {"@xmlns:isrctn": "http://www.67bricks.com/isrctn", "#text": "Other"}, "diseaseClass2": null}}, "interventions": {"intervention": {"description": "Randomly varied the colour on which the survey questionnaire was printed (five colours)", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18337536 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "4fafc73f-0e57-42ef-b6d7-070070f81f91", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-03-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18337536"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder14560-0", "contactId": "Contact52294_14560", "sponsorId": "Sponsor50779"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52294_14560", "title": "Dr", "forename": "Ross", "surname": "Upshur", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "2075 Bayview Avenue\nRoom E3-49", "city": "Toronto, ON", "country": "Canada", "zip": "M4N 3M5", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+1 416 480 4753"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ross.upshur@sw.ca"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50779", "organisation": "Sunnybrook and Women's College Health Sciences Centre (Canada)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "2075 Bayview Avenue\nRoom E3-49", "city": "Toronto, ON", "country": "Canada", "zip": "M4N 3M5", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+1 416 480 4753"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ross.upshur@sw.ca"}}, "privacy": "Public", "gridId": "grid.413104.3", "rorId": "https://ror.org/03wefcv03"}, "funder": {"@id": "Funder14560-0", "name": "Sunnybrook and Women's College Health Sciences Centre (Canada)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2006-01-09T00:00:00.000Z", "#text": "19105863"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Dutch Intraventricular Thrombolysis in Cerebral Haemorrhage study", "scientificTitle": null, "acronym": "DITCH", "studyHypothesis": "In patients with intraventricular haemorrhage (IVH) caused by extension from an intracerebral haemorrhage (ICH), ventricular drainage combined with intraventricular thrombolysis improves three month outcome when compared to standard treatment.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Poor outcome at three months (mRankin scale and GOS).", "secondaryOutcome": "1. Drain dependency at 3 months\n2. Amsterdam Linear Disability Scale score at 3 months\n3. Intraventricular or parenchymal bleeding complications\n4. Ventriculitis", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN19105863", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR496"}, "trialDesign": {"studyDesign": "Multicentre randomised single blind active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-02-01T00:00:00.000Z", "overallEndDate": "2008-02-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "b44e2711-c34b-4b52-b7db-a81dded6e253", "name": "Academic Medical Center", "address": null, "city": "Amsterdam", "state": null, "country": "Netherlands", "zip": "1100 DD"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Age >18 years\n2. IVH caused by extension of spontaneous ICH confirmed by computed tomography (CT) scan \n3. Glasgow Coma Score on admission of <14\n4. Able to include patients within 48 hours after ICH onset\n5. Historical mRankin of 0 or 1", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "46", "totalFinalEnrolment": null, "totalTarget": "46", "exclusion": "1. IVH caused by aneurysm or arteriovenous malformation as seen on CT-scan\n2. Only sedimentation of blood in the lateral ventricles\n3. Infratentorial bleeding\n4. Evacuation of parenchymal hematoma is deemed necessary\n5. Clotting disorder\n6. Pregnancy\n7. Epileptic seizure at onset \n8. Absence of brain stem reflexes on admission\n9. If death appears imminent", "patientInfoSheet": null, "recruitmentStart": "2006-02-01T00:00:00.000Z", "recruitmentEnd": "2008-02-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Intraventricular haemorrhage, intracerebral haemorrhage", "diseaseClass1": "Circulatory System", "diseaseClass2": "Intracerebral haemorrhage"}}, "interventions": {"intervention": {"description": "External ventricular drain(s) (EVD) placement. Infusion of 3 mg tr-PA through the EVD twice daily with a maximum of six days, compared to extraventricular drainage alone.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder14590-0", "contactId": "Contact52320_14590", "sponsorId": "Sponsor50818"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52320_14590", "title": "Dr", "forename": "K.", "surname": "Gans, de", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Academic Medical Center\nDepartment of Neurology\nP.O. Box 22660", "city": "Amsterdam", "country": "Netherlands", "zip": "1100 DD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)20 5663842"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "K.deGans@amc.uva.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor50818", "organisation": "Academic Medical Centre (AMC) (Netherlands)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "Department of Neurology \nP.O. Box 22660", "city": "Amsterdam", "country": "Netherlands", "zip": "1100 DD", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5650.6", "rorId": "https://ror.org/03t4gr691"}, "funder": {"@id": "Funder14590-0", "name": "Academic Medical Centre (AMC) (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2004-12-06T00:00:00.000Z", "#text": "76536440"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Washed blood components in adult acute leukemia", "scientificTitle": null, "acronym": null, "studyHypothesis": "Not provided at time of registration", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Added 14/08/09:\n1. Platelet transfusion refractoriness\n2. Infectious and bleeding complications \n3. Overall survival.", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN76536440", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "1991-01-01T00:00:00.000Z", "overallEndDate": "1994-12-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "United States of America"}, "trialCentres": {"trialCentre": {"@id": "e36f1601-c4cb-4949-9536-9d88fd11a902", "name": "601 Elmwood Avenue", "address": null, "city": "Rochester", "state": null, "country": "United States of America", "zip": "14642"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Adult patients with acute leukemia undergoing full dose remission induction chemotherapy.", "ageRange": "Adult", "gender": "Not Specified", "targetEnrolment": "43", "totalFinalEnrolment": null, "totalTarget": "43", "exclusion": "Does not match inclusion criteria", "patientInfoSheet": null, "recruitmentStart": "1991-01-01T00:00:00.000Z", "recruitmentEnd": "1994-12-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Acute Leukemia", "diseaseClass1": "Cancer", "diseaseClass2": "Leukaemia of unspecified cell type"}}, "interventions": {"intervention": {"description": "The control intervention was leukocyte reduced red cell and platelet transfusions, the standard practice in most hospitals.\nThe experimental intervention was leukocyte reduced red cell and platelet transfusions that had also been plasma reduced by washing.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15588315 results", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "edb2d1df-b91f-48db-97ec-8eed8c0467c4", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-12-10T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/15588315"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": ["Funder12820-0", "Funder12820-1"], "contactId": "Contact50293_12820", "sponsorId": "Sponsor48664"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50293_12820", "title": "Dr", "forename": "Neil", "surname": "Blumberg", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "601 Elmwood Avenue\nBox 608", "city": "Rochester", "country": "United States of America", "zip": "14642", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+1 585 275 9656"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "neil_blumberg@urmc.rochester.edu"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor48664", "organisation": "University of Rochester (USA)", "website": null, "sponsorType": "University/education", "contactDetails": {"address": "601 Elmwood Avenue", "city": "Rochester", "country": "United States of America", "zip": "14642", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "neil_blumberg@urmc.rochester.edu"}}, "privacy": "Public", "gridId": "grid.16416.34", "rorId": "https://ror.org/022kthw22"}, "funder": [{"@id": "Funder12820-0", "name": "University of Rochester (USA)", "fundRef": null}, {"@id": "Funder12820-1", "name": "CaridianBCT Inc. (formerly Gambro BCT Inc.) (USA)", "fundRef": null}]}, {"trial": {"@lastUpdated": "2009-08-14T00:00:00.000Z", "@version": "16", "isrctn": {"@dateAssigned": "2003-10-27T00:00:00.000Z", "#text": "45171788"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Neuropsychological rehabilitation: Modular cognitive retraining versus compensatory skills training", "scientificTitle": null, "acronym": null, "studyHypothesis": "A randomised controlled trial on neuropsychological rehabilitation", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration.", "secondaryOutcome": "Not provided at time of registration.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN45171788", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "B8"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2002-04-01T00:00:00.000Z", "overallEndDate": "2005-04-30T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Germany"}, "trialCentres": {"trialCentre": {"@id": "bc43401c-8216-4c14-ab51-110e731d53e8", "name": "Medical Director", "address": null, "city": "Schaufling", "state": null, "country": "Germany", "zip": "94571"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Neuropsychological impairments in at least two of the cognitive domains (cf. International Classification of Functioning, Disability and Health [ICF], World Health Organisation [WHO]): attention, memory, or problem solving\n2. Age 16 to 55 years\n3. Participation in the therapy programme for 5 weeks\n4. Barthel Index at least summary score 40", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "0", "totalFinalEnrolment": null, "totalTarget": "Not provided at time of registration.", "exclusion": "1. Prior brain injury to the actual trauma\n2. Psychiatric disorder before trauma medically documented\n3. Substance abuse\nThe participants are all inpatients at the neuropsychological rehabilitation centres. They are no longer in emergency units but in therapeutic care for the reintegration in job, family and daily life.", "patientInfoSheet": null, "recruitmentStart": "2002-04-01T00:00:00.000Z", "recruitmentEnd": "2005-04-30T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Severe head trauma, stroke", "diseaseClass1": "Injury, Occupational Diseases, Poisoning", "diseaseClass2": "Intracranial injury"}}, "interventions": {"intervention": {"description": "Compensatory skills training versus retraining basic cognitive impairments (either memory skills training or problemsolving)     \naddititional for both therapies\n\"living with neuropsychological impairment\" and attention training", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder5148-0", "contactId": "Contact5577_5148", "sponsorId": "Sponsor5262"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact5577_5148", "title": "Dr", "forename": "Peter", "surname": "Frommelt", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Medical Director\nAsklepios Klinik Schaufling\nHaustein 2", "city": "Schaufling", "country": "Germany", "zip": "94571", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+49 (0)9904 775571"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "p.frommelt@asklepios.com"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5262", "organisation": "Bavarian Network for Rehabilitation Research (Rehabilitationswissenschaftlicher Forschungsverbund Bayern) (Germany)", "website": null, "sponsorType": "Research organisation", "contactDetails": {"address": "RFB-Gesch\u00e4ftsstelle\nWilmar Igl\nc/o Institut f\u00fcr Psychotherapie und Medizinische Psychologie der Universit\u00e4t W\u00fcrzburg\nMarcusstr.9-11", "city": "W\u00fcrzburg", "country": "Germany", "zip": "97070", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "funder": {"@id": "Funder5148-0", "name": "Bavarian Network for Rehabilitation Research (Rehabilitationswissenschaftlicher Forschungsverbund Bayern) (Germany)", "fundRef": null}}]}}